Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 841

1.

ST-segment elevation myocardial infarction.

Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, Gibson CM, Goto S, Katus HA, Kerneis M, Kimura T, Kunadian V, Pinto DS, Shiomi H, Spertus JA, Steg PG, Mehran R.

Nat Rev Dis Primers. 2019 Jun 6;5(1):39. doi: 10.1038/s41572-019-0090-3. Review.

PMID:
31171787
2.

Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS investigators.

Gastroenterology. 2019 May 29. pii: S0016-5085(19)40974-8. doi: 10.1053/j.gastro.2019.05.056. [Epub ahead of print]

PMID:
31152740
3.

P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.

Povsic TJ, Ohman EM, Roe MT, White J, Rockhold FW, Montalescot G, Cornel JH, Nicolau JC, Steg PG, James S, Bode C, Welsh RC, Plotnikov AN, Mundl H, Gibson CM.

JAMA Cardiol. 2019 May 29. doi: 10.1001/jamacardio.2019.1510. [Epub ahead of print]

PMID:
31141104
4.

Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.

Joyce LC, Baber U, Claessen BE, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Ariti C, Dangas G, Faggioni M, Aoi S, Gibson CM, Aquino M, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Guedeney P, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.

JACC Cardiovasc Interv. 2019 May 27;12(10):983-992. doi: 10.1016/j.jcin.2019.02.033.

PMID:
31122354
5.

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.

White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG.

Eur Heart J. 2019 May 23. pii: ehz299. doi: 10.1093/eurheartj/ehz299. [Epub ahead of print]

PMID:
31121022
6.

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.

Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators.

Circulation. 2019 May 23. doi: 10.1161/CIRCULATIONAHA.118.038840. [Epub ahead of print]

PMID:
31117810
7.

Alirocumab after Acute Coronary Syndrome. Reply.

Schwartz GG, Steg PG, Szarek M.

N Engl J Med. 2019 May 23;380(21):2077. doi: 10.1056/NEJMc1902955. No abstract available.

PMID:
31116934
8.

Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF, Becker RC, Lopes RD; PLATO Investigators.

Am Heart J. 2019 Apr 18;213:57-65. doi: 10.1016/j.ahj.2019.04.006. [Epub ahead of print]

PMID:
31108273
9.

Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko A, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S; COMPASS investigators.

Gastroenterology. 2019 May 2. pii: S0016-5085(19)36764-2. doi: 10.1053/j.gastro.2019.04.041. [Epub ahead of print]

PMID:
31054846
10.

Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.

Bhatt DL, Steg PG, Miller M.

N Engl J Med. 2019 Apr 25;380(17):1678. doi: 10.1056/NEJMc1902165. No abstract available.

PMID:
31018077
11.

Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.

Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG.

Arch Cardiovasc Dis. 2019 Apr 20. pii: S1875-2136(19)30075-0. doi: 10.1016/j.acvd.2019.02.003. [Epub ahead of print]

PMID:
31014991
12.

Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.

Faggioni M, Baber U, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Claessen BE, Dangas GD, Gibson CM, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Farhan S, Ariti C, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.

Circ Cardiovasc Interv. 2019 Apr;12(4):e007133. doi: 10.1161/CIRCINTERVENTIONS.118.007133.

PMID:
30998384
13.

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.

Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM.

Clin Chem. 2019 Jun;65(6):781-790. doi: 10.1373/clinchem.2018.298489. Epub 2019 Apr 15.

PMID:
30988169
14.

Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease versus other European countries: data from the CLARIFY registry.

Parma Z, Young R, Roleder T, Marona M, Ford I, Tendera M, Steg PG, Stępińska J.

Pol Arch Intern Med. 2019 Apr 5;129(5):327-334. doi: 10.20452/pamw.14789. Epub 2019 Apr 5.

15.

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1.

PMID:
30928824
16.

Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial.

Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Mar 12. pii: S0735-1097(19)33921-X. doi: 10.1016/j.jacc.2019.03.013. [Epub ahead of print]

17.

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators.

J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.

18.

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial.

Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Spitzer E, Walsh SJ, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen JGP, Rademaker-Havinga T, Garg S, Steg PG, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt FWA.

EuroIntervention. 2019 Mar 19. pii: EIJ-D-19-00202. doi: 10.4244/EIJ-D-19-00202. [Epub ahead of print]

19.

Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment.

Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007445. doi: 10.1161/CIRCINTERVENTIONS.118.007445.

PMID:
30871355
20.

Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.

Palmerini T, Bruno AG, Gilard M, Morice MC, Valgimigli M, Montalescot G, Collet JP, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007541. doi: 10.1161/CIRCINTERVENTIONS.118.007541.

PMID:
30871353
21.

Impact of Low Ankle-Brachial Index on the Risk of Recurrent Vascular Events.

Abboud H, Monteiro Tavares L, Labreuche J, Arauz A, Bryer A, Lavados PM, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Amarenco P.

Stroke. 2019 Apr;50(4):853-858. doi: 10.1161/STROKEAHA.118.022180.

PMID:
30852970
22.

Pre-treatment with a P2Y12 antagonist before PCI in STEMI: why should we wait?

Abtan J, Steg PG.

Eur Heart J. 2019 Apr 14;40(15):1211-1213. doi: 10.1093/eurheartj/ehz058. No abstract available.

PMID:
30851044
23.

Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study.

Chichareon P, Modolo R, van Klaveren D, Takahashi K, Kogame N, Chang CC, Katagiri Y, Tomaniak M, Asano T, Spitzer E, Buszman P, Prokopczuk J, Fath-Ordoubadi F, Buysschaert I, Anderson R, Oldroyd KG, Merkely B, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Onuma Y, Serruys PW.

Int J Cardiol. 2019 Jul 1;286:43-50. doi: 10.1016/j.ijcard.2019.02.043. Epub 2019 Feb 20.

PMID:
30846254
24.

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.

Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG.

J Am Coll Cardiol. 2019 Mar 26;73(11):1362-1364. doi: 10.1016/j.jacc.2019.01.016. Epub 2019 Feb 25. No abstract available.

PMID:
30819552
25.

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.

Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP.

Eur Heart J. 2019 May 14;40(19):1553-1562. doi: 10.1093/eurheartj/ehz059.

26.

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.

Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstråle W, Held C, Steg PG; THEMIS Steering Committee.

Clin Cardiol. 2019 May;42(5):498-505. doi: 10.1002/clc.23164. Epub 2019 Apr 9.

27.

Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.

Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators.

J Am Coll Cardiol. 2019 Feb 26;73(7):741-754. doi: 10.1016/j.jacc.2018.11.048.

PMID:
30784667
28.

Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study.

Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A.

Am J Med. 2019 Jan 18. pii: S0002-9343(19)30062-2. doi: 10.1016/j.amjmed.2018.12.032. [Epub ahead of print]

PMID:
30660573
29.

The DAPT Score in Sweden: Successful Validation, Flawed Interpretation.

Yeh RW, Kereiakes DJ, Secemsky EA, Steg PG, Mauri L.

J Am Coll Cardiol. 2019 Jan 8;73(1):113-114. doi: 10.1016/j.jacc.2018.10.053. No abstract available.

PMID:
30621941
30.

Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.

Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, Moliterno D, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R.

Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e004945. doi: 10.1161/CIRCOUTCOMES.118.004945.

PMID:
30606052
31.

β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.

Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, Tendera M, Ferrari R, Merkely B, Parkhomenko A, Reid C, Tardif JC, Fox KM.

Eur Heart J. 2018 Dec 27. doi: 10.1093/eurheartj/ehy811. [Epub ahead of print]

32.

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.

Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Diaz R, Van de Werf F, Corbalán R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS.

J Am Heart Assoc. 2018 Nov 20;7(22):e009260. doi: 10.1161/JAHA.118.009260.

33.

Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.

Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm C, Price MJ, Prats J, Elkin S, Deliargyris EN, White HD, Menozzi A, Harrington RA, Bhatt DL; MPH on Behalf of the CHAMPION PHOENIX Investigators.

Int J Cardiol. 2019 Mar 1;278:217-222. doi: 10.1016/j.ijcard.2018.11.114. Epub 2018 Nov 23.

34.

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.

Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Feb 5;73(4):387-396. doi: 10.1016/j.jacc.2018.10.039. Epub 2018 Nov 11.

35.

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L.

JAMA Cardiol. 2018 Nov 14. doi: 10.1001/jamacardio.2018.3811. [Epub ahead of print]

PMID:
30427997
36.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators.

N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.

PMID:
30415628
37.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
38.

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.

Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB Sr, Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG, Visseren FLJ.

J Am Heart Assoc. 2018 Aug 21;7(16):e009217. doi: 10.1161/JAHA.118.009217.

39.

Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).

Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL.

Am J Cardiol. 2019 Jan 1;123(1):145-152. doi: 10.1016/j.amjcard.2018.09.014. Epub 2018 Sep 26.

PMID:
30366601
40.

Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women.

Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L; DAPT Study Investigators.

Circ Cardiovasc Interv. 2018 Aug;11(8):e005308. doi: 10.1161/CIRCINTERVENTIONS.117.005308.

PMID:
30354781
41.

[Fourth universal definition of myocardial infarction (2018)].

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL Jr, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM Jr, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O'Gara PT, Fox KAA.

Kardiol Pol. 2018;76(10):1383-1415. doi: 10.5603/KP.2018.0203. Polish. No abstract available.

42.

Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry).

Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, Farhan S, Sharma M, Ariti C, Dangas G, Gibson M, Faggioni M, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.

Am J Cardiol. 2018 Nov 15;122(10):1638-1646. doi: 10.1016/j.amjcard.2018.07.041. Epub 2018 Aug 20.

PMID:
30270177
43.

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.

Stone GW, Généreux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J, Deliargyris EN, Bhatt DL.

Eur Heart J. 2018 Dec 7;39(46):4112-4121. doi: 10.1093/eurheartj/ehy562. Erratum in: Eur Heart J. 2019 Apr 14;40(15):1201.

44.

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.

Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS Investigators.

Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27.

PMID:
30166073
45.

The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patients.

Vidal-Petiot E, Elbez Y, Lüscher TF, Fox KM, Steg PG.

Eur Heart J. 2018 Dec 1;39(45):4040-4041. doi: 10.1093/eurheartj/ehy495. No abstract available.

PMID:
30165378
46.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.

47.

Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry.

Vidal-Petiot E, Sorbets E, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG.

Eur Heart J. 2018 Nov 14;39(43):3855-3863. doi: 10.1093/eurheartj/ehy488.

48.

Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events).

Worme MD, Tan MK, Armstrong DWJ, Yan AT, Tan NS, Brieger D, Budaj A, Gore JM, López-Sendón J, Van de Werf F, Steg PG, Fox KAA, Goodman SG, Udell JA.

Am J Cardiol. 2018 Sep 15;122(6):944-951. doi: 10.1016/j.amjcard.2018.06.001. Epub 2018 Jun 21.

PMID:
30115426
49.

Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy.

Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L; ARISTOTLE Investigators.

J Am Coll Cardiol. 2018 Aug 14;72(7):721-733. doi: 10.1016/j.jacc.2018.05.058.

PMID:
30092948
50.

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.

Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet JP, Gibson CM, Steg PG, Lopes RD, Gwon HC, Storey RF, Franchi F, Bhatt DL, Serruys PW, Angiolillo DJ.

Nat Rev Cardiol. 2018 Aug;15(8):480-496. doi: 10.1038/s41569-018-0049-1. Review.

PMID:
29973709

Supplemental Content

Support Center